Analytical Data
-
Gene name
CDC25
- Application
-
Alternative Names
CDC25A; CDC25A2; M-phase inducer phosphatase 1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P30304
-
Expression Region
Leu376~Leu524
-
Molecular Weight
22kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDC25 phosphatases are a family of dual-specificity enzymes that play a pivotal role in regulating the cell cycle by dephosphorylating cyclin-dependent kinase (CDK) substrates, particularly during the G2/M transition. The proper functioning of CDC25 is crucial for cell cycle progression, and dysregulation of its activity is linked to various diseases, including cancer. Overexpression or mutation of CDC25 has been associated with poor prognosis in several tumor types, making it a potential target for therapeutic intervention. Research on recombinant CDC25 proteins has gained momentum as scientists aim to better understand their structural and functional properties. By expressing these proteins in suitable host systems, researchers can analyze their enzymatic activities, interactions with CDKs, and regulatory mechanisms. Additionally, the study of CDC25 in a controlled environment allows for the exploration of its role in cellular signaling pathways and its interactions with various cofactors and inhibitors. Insights gained from such investigations can contribute to the development of novel anticancer strategies that inhibit CDC25 activity, thereby providing a new avenue for targeted therapy in oncology. Ultimately, the ongoing research on CDC25 recombinant proteins not only enhances our understanding of cell cycle regulation but also holds significant promise for improving cancer treatment outcomes.
